Derik De Bruin
Stock Analyst at B of A Securities
(4.67)
# 167
Out of 5,090 analysts
221
Total ratings
67.57%
Success rate
16.75%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $145.49 | +13.41% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,414.86 | -1.76% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $226.25 | -2.76% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $39.16 | -31.05% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $100.79 | +9.14% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $48.03 | +4.10% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $17.77 | -26.84% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $47.01 | +12.74% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $394.81 | -5.02% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $7.09 | +55.15% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $101.06 | -35.68% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $11.90 | +34.45% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $572.77 | +15.23% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $225.85 | +4.05% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $184.31 | +13.94% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $280.23 | +26.68% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $22.11 | +17.59% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $258.39 | +4.88% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $182.51 | -0.28% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $14.24 | +47.47% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $17.64 | +81.41% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $128.96 | -22.46% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.97 | +14.71% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.12 | +316.67% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.88 | +245.74% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $185.80 | +39.94% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.25 | +1,197.30% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $118.65 | +1.14% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.16 | +316.67% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $714.10 | -67.09% | 3 | Nov 2, 2018 |
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $145.49
Upside: +13.41%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,414.86
Upside: -1.76%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $226.25
Upside: -2.76%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $39.16
Upside: -31.05%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $100.79
Upside: +9.14%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $48.03
Upside: +4.10%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $17.77
Upside: -26.84%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $47.01
Upside: +12.74%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $394.81
Upside: -5.02%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $7.09
Upside: +55.15%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $101.06
Upside: -35.68%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $11.90
Upside: +34.45%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $572.77
Upside: +15.23%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $225.85
Upside: +4.05%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $184.31
Upside: +13.94%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $280.23
Upside: +26.68%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.11
Upside: +17.59%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $258.39
Upside: +4.88%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $182.51
Upside: -0.28%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $14.24
Upside: +47.47%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $17.64
Upside: +81.41%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $128.96
Upside: -22.46%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.97
Upside: +14.71%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.12
Upside: +316.67%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.88
Upside: +245.74%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $185.80
Upside: +39.94%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.25
Upside: +1,197.30%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $118.65
Upside: +1.14%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.16
Upside: +316.67%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $714.10
Upside: -67.09%